NeuroDerm Makes Progress On Simplified Path To Parkinson's Approval

NeuroDerm Ltd. reported Phase II results for its drug-device combination product ND0612 that reinforce its ability to fill a gap in the treatment of advanced Parkinson's disease, and it could be on the market in the US in less than three years if the company is able to stay on its revised development path.

Human brain illustrated with millions of small nerves - Conceptual 3d render

ND0612 uses an external pump to provide continuous delivery of carbidopa and levodopa in an attempt to prevent "off" periods that patients experience when oral versions of the drugs stop working before it is time to take another dose. Rehovot, Israel-based NeuroDerm is positioning the product candidate as a first-line treatment for advanced Parkinson's patients who otherwise would transition from oral therapy to AbbVie Inc.'s Duopa (carbidopa/levodopa enteral suspension) or deep brain stimulation – treatments that both require surgical procedures.

Scrip spoke with NeuroDerm CEO Oded Lieberman in January during the J.P. Morgan Healthcare Conference about the value that ND0612...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

UCB Follows Fellow European Pharmas With Major US Investment

13 Jun 2025

• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

12 Jun 2025

• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

12 Jun 2025

• By Joseph Haas, Lisa Takagi, Jung Won Shin, Vibha Ravi, and Sushmita Panda

Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.